AUS
NZ
UK
CA
USA
IND
Highlights:
-
GSK PLC has agreed to pay up to $2.2 billion to settle approximately 80,000 US lawsuits related to its heartburn medication, Zantac.
-
The settlement resolves 93% of state court cases, while GSK maintains there is no evidence linking Zantac to cancer risks.
-
Deutsche Bank has upgraded GSK's stock rating to 'buy' following the settlement announcement, indicating improved investor confidence.
GSK PLC {LSE:GSK} has reached an agreement to pay up to $2.2 billion to settle around 80,000 lawsuits filed in the United States concerning its heartburn medication Zantac, which is generically known as ranitidine. The plaintiffs in these cases allege that the medication caused cancer. Despite these claims, GSK asserts that there is no evidence connecting Zantac to an increased risk of cancer and has not admitted liability in the matter.
This settlement is significant as it resolves approximately 93% of the ongoing state court cases related to Zantac. GSK anticipates that the settlement process will be completed by mid-2025. Additionally, the company will pay $70 million to settle a separate claim made by Valisure, a laboratory that raised concerns about the presence of a carcinogen in Zantac.
To fund these settlements, GSK will utilize its existing financial resources, and it has indicated that its commitment to research and development will remain unchanged. The company anticipates a charge of £1.8 billion in its third-quarter 2024 results, which is expected to be partially offset by reduced legal costs, thereby alleviating some financial uncertainty surrounding the ongoing litigation.
In response to the settlement announcement, Deutsche Bank commented that GSK has become “investable again,” suggesting that the resolution of these legal challenges may enhance the company’s appeal to the market. The bank noted that the circumstances surrounding GSK had become increasingly complex, but the positive outcome in the Zantac litigation provides a promising development. Deutsche Bank has upgraded its rating on GSK’s shares to 'buy,' indicating a price target of up to 1,850 pence per share, while the stock closed at 1,458 pence on Wednesday.
